BioCentury
ARTICLE | Company News

Acucela slides after Otsuka ends ophthalmic deals

June 15, 2016 12:23 AM UTC

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429) and Otsuka's OPA-6566.

Last month, Acucela said emixustat missed the primary endpoint of a Phase IIb/III study to treat geographic atrophy secondary to age-related macular degeneration (AMD) (see BioCentury Extra, May 26). ...